The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice
Open accessAbstract
In obese humans and rodents there is increased expression of the key glucocorticoid (GC) regenerating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), in adipose tissue. This increased expression appears to be of pathogenic importance because transgenic mice overexpressing 11β-HSD1 selectively in adipose tissue exhibit a full metabolic syndrome with visceral obesity, dyslipidemia, insulin-resistant diabetes, and hypertension. In this model, while systemic plasma GC levels are unaltered, GC delivery to the liver via the portal vein is increased. 11β-HSD1 is most highly expressed in liver where inhibition or deficiency of its activity improves glucose and lipid homeostasis. To determine the potential contribution of elevated intrahepatic GCs alone toward development of insulin-resistant syndromes we generated transgenic mice expressing increased 11β-HSD1 activity selectively in the liver under transcriptional control of hepatic regulatory sequences derived from the human apoE gene (apoE-HSD1). Transgenic lines with 2- and 5-fold-elevated 11β-HSD1 activity exhibited mild insulin resistance without altered fat depot mass. ApoE-HSD1 transgenic mice exhibited fatty liver and dyslipidemia with increased hepatic lipid synthesis/flux associated with elevated hepatic LXRα and PPARα mRNA levels as well as impaired hepatic lipid clearance. Further, apoE-HSD1 transgenic mice have a marked, transgene-dose-associated hypertension paralleled by incrementally increased liver angiotensinogen expression. These data suggest that elevated hepatic expression of 11β-HSD1 may relate to the pathogenesis of specific fatty liver, insulin-resistant, and hypertensive syndromes without obesity in humans as may occur in, for example, myotonic dystrophy, and possibly, the metabolically obese, normal-weight individual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Self-citationMolecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors
Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487
Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., & Mangelsdorf, D. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81432-4 · Cited by 1,436
Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7473 · Cited by 943
The metabolically obese, normal-weight individual revisited.
Ruderman, N., Chisholm, D., Pi-Sunyer, X., & Schneider, S. (1998) · Diabetes · doi:10.2337/diabetes.47.5.699 · Cited by 893
Kotelevtsev, Y., Holmes, M. C., Burchell, A., Houston, P. M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C. R. W., Seckl, J. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14924 · Cited by 858
Self-citationJoseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E., Walczak, R., Collins, J. L., Osborne, T. F., & Tontonoz, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111041200 · Cited by 779
The perils of portliness: causes and consequences of visceral adiposity.
Montague, C. T., & O'Rahilly, S. (2000) · Diabetes · doi:10.2337/diabetes.49.6.883 · Cited by 737
Cited by
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“glucose flux in these animals are not yet available (206).”
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Self-citationMitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Glucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535
Van Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Macfarlane, D. P., Forbes, S., & Walker, B. R. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0054 · Cited by 385
“…of Endocrinology (2008) 197, 189–204 Downloaded from Bioscientifica.com at 03/05/2022 04:59:15PM via free access fatty acid synthesis and lipid oxidation are basally upregulated, although the lipogenic response to high-fat feeding was attenuated compared with controls (Paterson et al. 2004).”
BackgroundInfluentialOverview of Animal Models of Obesity
Lutz, T. A., & Woods, S. C. (2012) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0561s58 · Cited by 375
Early-life stress, HPA axis adaptation, and mechanisms contributing to later health outcomes
Maniam, J., Antoniadis, C., & Morris, M. J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00073 · Cited by 295
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 287
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Wang, M. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-3 · Cited by 277
11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess
Morgan, S. A., McCabe, E. L., Gathercole, L. L., Hassan-Smith, Z. K., Larner, D. P., Bujalska, I. J., Stewart, P. M., Tomlinson, J. W., & Lavery, G. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323681111 · Cited by 272
Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance
Beaupere, C., Liboz, A., Fève, B., Blondeau, B., & Guillemain, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020623 · Cited by 271
Adipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity
Kershaw, E. E., Morton, N. M., Dhillon, H., Ramage, L., Seckl, J. R., & Flier, J. S. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1023 · Cited by 253
Self-citationMitochondrial fatty acid oxidation in obesity
Serra, D., Mera, P., Malandrino, M. I., Mir, J. F., & Herrero, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4875 · Cited by 246
“An increase in CPT1A expression has been reported in several rodent models (14, 134).”
11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
“els of corticosterone [206], nor does overexpression in fat [164] or the brain [102].”
Self-citationLavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Self-citationBujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C., Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01718 · Cited by 165
A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease
Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I. J., Doig, C., Newsome, P. N., Hubscher, S., Elias, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029531 · Cited by 115
“Transgenic mice overexpressing the 11b-HSD1 gene selectively in the liver under the transcriptional control of the human apoE gene, exhibit fatty liver (but not steatohepatitis) with increased hepatic triglyceride accumulation and impaired hepatic lipid clearance [26].”
BackgroundStimson, R. H., Mohd-Shukri, N. A., Bolton, J. L., Andrew, R., Reynolds, R. M., & Walker, B. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2307 · Cited by 74
Stimson, R. H., Andrew, R., McAvoy, N. C., Tripathi, D., Hayes, P. C., & Walker, B. R. (2011) · Diabetes · doi:10.2337/db10-0726 · Cited by 67
Witchel, S. F., & DeFranco, D. B. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0323 · Cited by 58
Hintzpeter, J., Stapelfeld, C., Loerz, C., Martin, H.-J., & Maser, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084468 · Cited by 53
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Brief review: Glucocorticoid excretion in obesity
Müssig, K., Remer, T., & Maser-Gluth, C. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.01.008 · Cited by 36
Mark, P. J., Wyrwoll, C. S., Zulkafli, I. S., Mori, T. A., & Waddell, B. J. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-39 · Cited by 19
“A second key feature of the programmed adipose tissue phenotype was an apparent increase in glucocorticoid sensitivity, a characteristic linked to the aetiology of obesity [25-27].”
BackgroundThe effect of early-life stress and chronic high-sucrose diet on metabolic outcomes in female rats
Maniam, J., Antoniadis, C. P., & Morris, M. J. (2015) · Stress · doi:10.3109/10253890.2015.1079617 · Cited by 13
PEDF Expression Is Inhibited by Insulin Treatment in Adipose Tissue via Suppressing 11β-HSD1
Zhou, Y., Xu, F., Deng, H., Bi, Y., Sun, W., Zhao, Y., Chen, Z., & Weng, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084016 · Cited by 12
Metadata
- Authors
- Paterson, J. M., Morton, N. M., Fievet, C., Kenyon, C. J., Holmes, M. C., Staels, B., Seckl, J. R., & Mullins, J. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-04-26
- Volume
- 101
- Issue
- 18
- Pages
- 7088-7093
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2119251936
- Cited by
- 431
- References
- 56
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.